ArticleAmerican journal of cancer research2026
Serum inflammatory markers and influencing factors in patients with colorectal adenomas.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the expression patterns of serum inflammatory markers (SIMs) in patients with colorectal adenomas (CRAs) and identify the associated influencing factors. A total of 420 patients who underwent colonoscopy between January 2020 and December 2025 were included in this study. Patients with colonoscopy-identified CRAs were assigned to the CRA group (n=285), whereas individuals without obvious endoscopic abnormalities served as the control group (n=135). SIMs, including high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), as well as blood lipids, including total cholesterol (TC), triglyceride (TG), and high-/low-density lipoprotein cholesterol (HDL-C/LDL-C), were measured and compared between the two groups. CRA patients presented with higher TG levels, lower HDL-C levels, and elevated SIM levels compared with controls (P<0.05). Univariate analysis revealed significant between-group differences in age, smoking history, drinking history, hepatic steatosis, cholecystic polyps, gallstones, TG, and HDL-C. Logistic regression analysis demonstrated that older age, smoking, hypertriglyceridemia, low HDL-C levels, and elevated inflammatory marker levels were independent risk factors for CRAs. In conclusion, smoking, dyslipidemia, and chronic inflammation are independent factors associated with CRA development. In addition to lifestyle modification and lipid management, dynamic monitoring of inflammatory markers may have important clinical value for improving the early identification of individuals at high risk of CRAs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.